Malignant triton tumor of maxilla: A case report

Rajjyoti Das, Anupam Sarma, Partha Sarathi Chakraborty, Jagannath Dev Sharma, Amal Chandra Kataki

ABSTRACT

Introduction: Malignant triton tumor (or malignant Schwanoma with Rhabdomyoblastic differentiation) is a very rare entity with poor prognosis. It is considered a high grade malignant neoplasm with poor outcome. In 70% of cases the neoplasm is associated with von Recklinghausen neurofibromatosis and in the remaining 30% it is the sole morbid finding. Local recurrence is frequent and distant metastasis preferentially situated in lung and brain. Surgery is the treatment of choice and post operative radiotherapy is always indicated. Histopathology and immunohistochemistry are helpful in diagnosis. We report clinical course, therapeutic approach, histopathology and immunohistochemistry of such a case.

Case Report: A 19-year-old female presented in Dr B Borooah Cancer Institute, Guwahati with a complaint of swelling in the right side of the cheek with ulceration in the oral cavity. On clinical examination there was a round swelling in left cheek of 4x4 cm size with overlying normal skin. Computed tomography scan revealed a hypo dense lesion in the right maxillary sinus with erosion of the floor. Punch biopsy was taken from palatal growth and sent for histopathological examination which revealed a malignant neoplasm with sarcomatoid features composed of spindle cells. Immunohistochemical stains showed tumor cells positive for Vimentin, S-100 protein and Desmin. Patient was taken up for surgery followed by radiotherapy.

Conclusion: Malignant triton tumor of maxilla is extremely rare. The diagnosis must be based upon imaging study, histopathology and immunohistochemical features. Considering the aggressive nature of disease radical surgery should be followed by adjuvant chemoradiation.
Malignant triton tumor of maxilla: A case report

Rajjyoti Das, Anupam Sarma, Partha Sarathi Chakraborty, Jagannath Dev Sharma, Amal Chandra Kataki

ABSTRACT

Introduction: Malignant triton tumor (or malignant Schwannoma with Rhabdomyoblastic differentiation) is a very rare entity with poor prognosis. It is considered a high grade malignant neoplasm with poor outcome. In 70% of cases the neoplasm is associated with von Recklinghausen neurofibromatosis and in the remaining 30% it is the sole morbid finding. Local recurrence is frequent and distant metastasis preferentially situated in lung and brain. Surgery is the treatment of choice and post operative radiotherapy is always indicated. Histopathology and immunohistochemistry are helpful in diagnosis. We report clinical course, therapeutic approach, histopathology and immunohistochemistry of such a case. Case Report: A 19-year-old female presented in Dr B Borooah Cancer Institute, Guwahati with a complaint of swelling in the right side of the cheek with ulceration in the oral cavity. On clinical examination there was a round swelling in left cheek of 4x4 cm size with overlying normal skin. Computed tomography scan revealed a hypodense lesion in the right maxillary sinus with erosion of the floor. Punch biopsy was taken from palatal growth and sent for histopathological examination which revealed a malignant neoplasm with sarcomatoid features composed of spindle cells. Immunohistochemical stains showed tumor cells positive for Vimentin, S-100 protein and, Desmin. Patient was taken up for surgery followed by radiotherapy. Conclusion: Malignant triton tumor of maxilla is extremely rare. The diagnosis must be based upon imaging study, histopathology and immunohistochemical features. Considering the aggressive nature of disease radical surgery should be followed by adjuvant chemoradiation.

Keywords: Malignant triton tumor (MTT), Surgery, Histopathology and immunohistochemistry

How to cite this article

Das R, Sarma A, Chakraborty P. Malignant triton tumor of maxilla: A case report. International Journal of Case Reports and Images 2014;5(2):160–164. doi:10.5348/ijcri-2014-02-463-CR-15

INTRODUCTION

Malignant peripheral nerve sheath tumor (MPNST) accounts for about 5–15% of all soft tissue sarcomas [1]. Malignant Triton Tumor (MTT) constitutes about 5% of all MPNSTs [2]. Common sites for MTT include head, neck, extremities and trunk [1–3]. This rare tumor with fewer cases reported in literature, generally affects adult patients but can also occur in children [4]. Morphology
and immunohistochemistry are helpful in diagnosis. A 5-year survival is low up to 10–20% indicating the high malignant nature of the disease [5]. Surgical resection of the tumor is thought to be best but due to its aggressive nature adjunct chemotherapy and radiotherapy may increases the survival [6, 7].

CASE REPORT

A 19-year-old female reported in the head and neck oncology out patient department with a complaint of swelling in the right side of the cheek since one and half months, with ulceration in the oral cavity since 25 days and pain in the right upper teeth with occasional bleeding from the mouth. On general examination she was average built. Respiratory and cardiovascular examination was normal. On ear, nose and throat clinical examination there was a round swelling in right cheek of 4x4 cm size with overlying normal skin. On palpation tenderness was present over the swelling with normal sensory finding. Intra oral examination revealed an irregular surface ulcer in the right side of hard palate with loose premolar and molar tooth. Neck examination revealed no cervical lymphadenopathy. Indirect laryngoscopic examination was normal. All other hematological examination and chest radiogram were normal.

Computed tomography (CT) scan revealed a hypodense lesion in the right maxillary sinus with erosion of the floor, there was enhancement of the lesion in contrast study (Figure 1). Punch biopsy was taken from palatal growth and sent for histopathological examination (HPE). The HPE revealed a malignant neoplasm with sarcomatoid features composed of spindle cells (Figure 2). The malignant cells showed hyperchromatic nuclei and pale cytoplasm. Differential diagnosis for spindle cell sarcoma includes malignant peripheral nerve sheath tumor (MPNST), spindle cell carcinoma, monophasic synovial sarcoma and spindle cell form of malignant melanoma. Immunohistochemical stains showed tumor cells positive for Vimentin, subsets of tumor cells positive for S-100 protein and another subset of tumor cells was positive for Desmin (Figures 3, 4). Immunohistochemistry was negative for CK, HMB-45 and chromogranin.

Patient was taken up for surgery. With a Weber-Ferguson incision right maxilla was approached and it was found that growth eroded the anterior maxillary wall and whole tumor was removed enblock including the involved palatal part. Tumor free margins was obtained at the time of surgical resection macroscopically and temporary palatal prosthesis was applied. Three weeks following surgery a final prosthesis was applied.

Specimen consisted of multiple fragments of bone, fibrous tissue and tumor mass which weighed 16.3 gm measuring 5x4x3 cm. On cut surface it was composed of grey firm tissue with cystic spaces. The tissue was sent for histopathological examination. HPE confirmed Malignant Triton tumor. Bone and cut margins were

Figure 1: Computed tomography (CT) scan showing disease extension of the patient.

Figure 2: Photomicrograph showing sarcomatoid spindle shaped tumor cells with variably pleomorphic and hyperchromatic nuclei and mitosis. (H&E, 100X).

Figure 3: Immunohistochemical staining showing subsets of tumor cells are positive for S-100. (S-100, 100X).
free of tumor. Three weeks following surgery patient was subjected to radiotherapy (66 Gy in 33 fractions for 6 weeks) over maxillae including upper neck.

**DISCUSSION**

Masson first described a lesion that consisted of a malignant schwannoma with rhabdomyoblastic differentiation [8]. Subsequently, Woodruff et al. coined the term “Malignant triton tumor” to indicate such a neoplasm [9]. There are two types of tumor, sporadic or in association with NF-1. Those with von Recklinghausen neurofibromatosis constitute over 70% and displayed a marked male predominance, young age with a common presentation in head and neck. On the other hand, those without von Recklinghausen neurofibromatosis are mostly common in older age, female predominance and frequently located on trunk [10].

MPNST can be diagnosed on histopathology supported by positivity for S-100 protein. In morphology most areas show appearance of an extremely cellular spindle cell neoplasm with abundant mitoses. Although most tumors are quite monomorphic but heterologous elements like rhabdomyoblasts, cartilage and bone may be present in some cases. Such tumors show positivity for S-100 protein in 50-90% of cases, suggesting a nerve sheath origin. Rhabdomyoblasts are positive for immunostains such as desmin, myogenin and myo-D1 [11].

Though MPNST is non-radio-sensitive, like other sarcomas, wide local surgical excision followed by adjuvant radical radiotherapy is mostly adequate. Role of chemotherapy is still not been clearly defined. But chemotherapy might play some role in adjuvant setting in eradicating micro metastasis [6, 7].

MTT has poor prognosis with 5 years survival rate of only 5–15%, where as MPNST has a good survival of about 50-60% [12]. Poor prognosis of MTT depends on the location, grade and total radical resection [13]. Prognosis is good in head, neck, and extremities but very poor in buttock and other sites.

In spite of adequate treatment, local recurrence and distant metastasis rates approximate 25 and 48%, respectively. Survival of patients with head and neck MTT ranges between four months and 22 years [11]. Cytogenetic study has revealed some karyotypic changes associated with this tumor. Cytogenetic analysis has revealed some breakpoints which are considered as region for myogenic differentiation and probably responsible for rhabdomyoblastic differentiation [14]. Aggressive biologic behavior is may be due to amplification of c-myc oncogene [15].

**CONCLUSION**

Malignant triton tumor of maxilla is extremely rare. The clinical presentation may be misleading. The diagnosis must be based upon imaging study, histopathology and immunohistochemical features as it was in our case. Additional physical signs of NF-1 should also be excluded. Considering the aggressive nature of disease radical treatment of surgery should be followed by adjuvant chemoradiation.

*********

**Author Contributions**

Rajjyoti Das – Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Critical revision of the article, Final approval of the version to be published

Anupam Sarma – Conception and design, Drafting the article, Critical revision of the article, Final approval of the version to be published

Partha Sarathi Chakraborty – Conception and design, Drafting the article, Critical revision of the article, Final approval of the version to be published

Jagannath Dev Sharma – Conception and design, Drafting the article, Critical revision of the article, Final approval of the version to be published

Amal Chandra Kataki – Conception and design, Critical revision of the article, Final approval of the version to be published

**Guarantor**
The corresponding author is the guarantor of submission.

**Conflict of Interest**
Authors declare no conflict of interest.

**Copyright**
© Rajjyoti Das et al. 2014; This article is distributed under the terms of Creative Commons attribution 3.0 License which permits unrestricted use, distribution and
REFERENCES

1. Weiss SW, Goldblum JR. Malignant tumors of peripheral nerves; In Weiss SW, Goldblum JR (eds): Enzinger and Weiss’s Soft Tissue Tumors, ed 5. China, Mosby Elsevier, 2008, pp 903-44. view article.

2. Brooks JSJ. Disorders of soft tissue; In Sternberg SS (ed): Diagnostic Surgical Pathology, ed 3. Philadelphia, Lipincott Williams and Wilkins, 1999, pp 131–221.

3. Zisis C, Fragoulis S, Rontogianni D, Stratakos G, Bellenis I. Malignant triton tumor of the anterior mediastinum as incidental finding: A case report. Monaldi Arch Chest Dis 2006 Dec;65(4):222–4.

4. Kim ST, Kim CW, Han GC, et al. Malignant triton tumor of the nasal cavity. Head Neck 2001 Dec;23(12):1075–8.

5. Mettinen M. Diagnostic soft tissue pathology. Washington, DC: Churchill Livingstone; 2003. pp 367–78.

6. McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012 Jul 1;106(1):51–6.

7. Theoennisse NH, Schiennemann C, Brunenberg U, et al. Chemotherapy in metastatic malignant triton tumor: Report on two cases. Oncol Rep 2007 Oct;18(4):763–7.

8. Masson P. Recklinghausen’s neurofibromatosis, sensory neuromas and motor neuromas. In: Libman anniversary. Vol 2. New York, NY: International Press, 1932:793–802.

9. Woodruff JM, Chernik NL, Smith MC, Millett WB, Foote FW Jr. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant “Triton” tumors). Cancer 1973 Aug;32(2):426–39.

10. Brooks JS, Freeman M, Enterline HT. Malignant “Triton” tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer 1985 Jun 1;55(11):2543–9.

11. Tripathy K, Mallik R, Mishra A, et al. A rare malignant triton tumor. Case Rep Neurol 2010 Jun 1;2(2):69–73.

12. Aldyami E, Dramis A, Grimer RJ, Abudu A, Carter SR, Tillman RM. Malignant triton tumor of the thigh—a retrospective analysis of nine cases. Eur J Surg Oncol 2006 Sep;32(7):808–10.

13. Terzic A, Bode B, Gratz KW, Stoeckli SJ. Prognostic factors for the malignant triton tumor of the head and neck. Head Neck 2009 May;31(5):679–88.

14. Haddadin MH, Hawkins AL, Long P, et al. Cytogenetic study of malignant triton tumor: A case report. Cancer Genet Cytogeten 2003 Jul 15;144(2):100–5.

15. Stasik CJ, Twafik O. Malignant peripheral nerve sheath with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med 2006 Dec;130(12):1878–8.

ABOUT THE AUTHORS

**Article citation:** Das R, Sarma A, Chakraborty P. Malignant triton tumor of maxilla: A case report. International Journal of Case Reports and Images 2014;5(2):160–164.

**Rajjyoti Das** is Senior Head & Neck Oncosurgeon at Dr B. Borooah Cancer Institute (Regional Cancer Center), Guwahati,Assam,India,with more than 10 years experience . His special interest in Microlaryngeal Laser & Reconstructive Oncosurgery. He is associated with DBT (India) project. He has few publications in National & International Journals. He intends to pursue post-doctoral fellowship in Head & Neck Oncology.

**Anupam Sarma** is Assistant Professor, Department of Pathology, Dr B. Borooah Cancer Institute, Guwahati,India. His area of interest is Oncopathology,Hemato-oncology,Molecular Pathology & Cancer Research. He intends to pursue some post-doctoral fellowship in the field of Oncopathology. He is associated with various research projects sponsored DBT & ICMR (Govt of India). He has more than 10 publications in International Journals.

**Partha Sarathi Chakraborty** is Fellow at Department of Head & Neck Oncology/ Dr B. Borooah Cancer Institute, Guwahati, Assam, India. His research interests includes Maxillofacial Oncology, He intends to pursue further training or fellowship in Head & Neck Microvascular Surgery in future.
Jagannath Dev Sharma is Professor & HOD in Department of Pathology at Dr B. Borooah Cancer Institute, Guwahati, India. He is also The Principal Investigator, Cancer Registry, ICMR (Govt. Of India). His fields of interest are Tumor Pathology, IHC, Molecular Pathology & Cancer Research. He has 22 international journal publications to his credit.

Amal Chandra Kataki is the Director of Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India, and Professor & Head of Department of Gynaecologic Oncology. He is actively involved in organizing MD & PhD programmes & Research on Molecular Biology of Cancer in addition to his routine clinical & administrative works. He is recipient of UICC fellowship. He has published 45 research papers in National & International journals.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open-access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.